SCHEMBL561403

SCHEMBL561403

Fc1cccc(CNC2=NCCN2)c1Cl

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.62
▸ GAA P10253 1/20 0.62
▸ APOBEC3A P31941 1/20 0.62
▸ CTDSP1 Q9GZU7 1/20 0.62
▸ APOBEC3G Q9HC16 1/20 0.62
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ NLRP3 Q96P20 1/20 0.50
▸ WDR5 P61964 12/20 0.49
▸ PTGIR P43119 1/20 0.47
▸ ADRA2A P08913 3/20 0.46
▸ ADRA2B P18089 3/20 0.46
▸ ADRA2C P18825 3/20 0.46
▸ ADRA1D P25100 2/20 0.46
▸ ADRA1A P35348 2/20 0.46
▸ ADRA1B P35368 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ SLC22A1 O15245 1/20 0.46
▸ SLC22A3 O75751 1/20 0.46
▸ HTR1A P08908 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13063071 0.86 LMNA (0.64) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL560655 0.86 ADRA2A (0.55) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL560405 0.85 LMNA (0.71) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL8139996 0.83 HTR1D (0.52) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL10022889 0.83 LMNA (0.62) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL20017860 0.83 SMN1; SMN2 (0.50) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL8133645 0.83 SMN1; SMN2 (0.50) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL560745 0.83 LMNA (0.55) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL560777 0.80 LMNA (0.56) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
Iodide SCHEMBL16227866 0.78 LMNA (0.59) LMNAGAAAPOBEC3ACTDSP1APOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2303264-B1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES ALLERGAN INC (US) 2018-04-04 — — EP claimed
EP-2932968-B1 COMPOUND FOR TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN INC (US) 2018-01-17 — — EP claimed
EP-2932968-A1 COMPOUND FOR TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2015-10-21 — — EP claimed
US-20150224080-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. 2015-08-13 — — US claimed
US-9034910-B2 Methods of treating alpha adrenergic mediated conditions ALLERGAN, INC. (US) 2015-05-19 — — US claimed
US-20120165380-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2012-06-28 — — US claimed
US-20120035235-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2012-02-09 — — US claimed
US-8071636-B2 Methods of treating alpha adrenergic mediated conditions ALLERGAN, INC. (US) 2011-12-06 — — US claimed
EP-2377534-A1 Methods of treating alpha adrenergic mediated conditions ALLERGAN, INC. (US) 2011-10-19 — — EP claimed
CN-102099032-A Methods of treating alpha adrenergic mediated conditions ALLERGAN INC 2011-06-15 — — CN claimed
EP-2303264-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS Allergan, Inc. (US) 2011-04-06 — — EP claimed
WO-2009152052-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2009-12-17 — — WO claimed
US-20090306161-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2009-12-10 — — US claimed
US-20230062049-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. 2023-03-02 — — US disclosed
US-20230062049-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. 2023-03-02 — — US disclosed
US-20200330428-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN INC (US) 2020-10-22 — — US disclosed
US-20090306398-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2009-12-10 — — US disclosed
US-20090306398-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2009-12-10 — — US disclosed
US-20090306398-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2009-12-10 — — US disclosed
US-20090306161-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ALLERGAN, INC. (US) 2009-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306161-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2C, ADRA2A LMNA 1467/4885GAA 751/4885APOBEC3A 3206/4885
US-20230062049-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2A, ADRA2C LMNA 1464/4885GAA 733/4885APOBEC3A 3241/4885
US-20150224080-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2A, ADRA2C LMNA 1464/4885GAA 733/4885APOBEC3A 3241/4885
US-20090306398-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2C, ADRA2A LMNA 1467/4885GAA 751/4885APOBEC3A 3206/4885
US-20120035235-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2C, ADRA2A LMNA 1467/4885GAA 751/4885APOBEC3A 3206/4885
US-20200330428-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2A, ADRA2C LMNA 1464/4885GAA 733/4885APOBEC3A 3241/4885
US-20120165380-A1 METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS ADRB2, ADRA2A, ADRA2C LMNA 1464/4885GAA 733/4885APOBEC3A 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback